Abstract: The invention provides for methods for treating Alzheimer's Disease in a subject by reducing ER-MAM localized APP-C99.

Abstract: The invention provides for methods for treating Alzheimer's Disease in a subject by reducing ER-MAM localized APP-C99.

Abstract: The invention provides for methods for treating Alzheimer's Disease in a subject by reducing ER-MAM localized APP-C99.

Abstract: The present disclosure describes a continuous anomaly detection method and system based on multi-dimensional behavior modeling and heterogeneous information analysis. A method includes collecting data, processing and categorizing a plurality of events, continuously clustering the plurality of events, continuously model building for behavior and information analysis, analyzing behavior and information based on a holistic model, detecting anomalies in the data, displaying an animated and interactive visualization of a behavioral model, and displaying an animated and interactive visualization of the detected anomalies.

Abstract: The present disclosure describes a continuous anomaly detection method and system based on multi-dimensional behavior modeling and heterogeneous information analysis. A method includes collecting data, processing and categorizing a plurality of events, continuously clustering the plurality of events, continuously model building for behavior and information analysis, analyzing behavior and information based on a holistic model, detecting anomalies in the data, displaying an animated and interactive visualization of a behavioral model, and displaying an animated and interactive visualization of the detected anomalies.

Abstract: The present disclosure describes a continuous anomaly detection method and system based on multi-dimensional behavior modeling and heterogeneous information analysis. A method includes collecting data, processing and categorizing a plurality of events, continuously clustering the plurality of events, continuously model building for behavior and information analysis, analyzing behavior and information based on a holistic model, detecting anomalies in the data, displaying an animated and interactive visualization of a behavioral model, and displaying an animated and interactive visualization of the detected anomalies.

Abstract: The present invention provides methods that are useful for the diagnosis of neurodegenerative disease or disorder and for the screening of compounds or therapeutic agents for treating a neurodegenerative disease or disorder. The methods pertain in part to the correlation of a neurodegenerative disease or disorder with abnormal or altered endoplasmic reticulum-mitochondrial-associated membranes (ER-MAM) integrity.

Abstract: The present invention provides a method for introducing a functional peptide encoded by a plant or protist nucleic acid sequence into a mitochondrion of a mammalian cell, and a pharmaceutical composition comprising the nucleic acid sequence. The present invention also provides a method for correcting a phenotypic deficiency in a mammal resulting from a mutation in a mitochondrial peptide. Additionally, the present invention is directed to a method for treating a mitochondrial disorder in a subject in need of treatment therefor. The present invention further provides expression vectors for use in introducing a functional peptide encoded by a plant or protist (including algal) nucleic acid sequence into a mitochondrion of a mammal, as well as mammalian cells transformed by the expression vectors. Also provided are clonal cell strains comprising the transformed mammalian cells. Finally, the present invention is directed to a method for introducing a functional peptide into a mitochondrion.

Abstract: The present invention provides a method for detecting a mutation in a nucleic acid molecule which comprises contacting the nucleic acid molecule with a probe. The probe comprises two covalently linked nucleic acid segments under conditions such that the unlinked end of each segment of the probe is capable of hybridizing with the nucleic acid molecule. This mixture is then contacted with a ligase under conditions such that the two hybridized probe segments will ligate and bind the nucleic acid molecule if the nucleic acid molecule contains the mutation. One would then determine the presence of bound nucleic acid molecule(s) and thereby detect the mutation in the nucleic acid molecule.

Abstract: The present invention provides methods for introducing functional peptides into organelles. Additionally, the present invention provides a method for correcting a phenotypic deficiency in a mammal that results from a mutation in the mammal's mitochondrial DNA (mtDNA). The present invention further provides a method for treating a mitochondrial disorder in a subject in need of treatment therefor. Also provided is an expression vector that is useful for introducing a functional peptide encoded by an mtDNA sequence into a mitochondrion. The present invention also provides eukaryotic cells transformed by expression vectors that are useful for introducing functional peptides into organelles. Finally, the present invention provides a pharmaceutical composition comprising a non-nuclear nucleic acid sequence encoding a peptide for introduction into an organelle, a nucleic acid sequence encoding an organelle-targeting signal, and a pharmaceutically-acceptable carrier.

Abstract: This invention provides compositions of matter, methods and kits for detecting the presence of a predefined nucleotide at a predefined position in a nucleic acid. The subject invention has numerous uses including, for example, the diagnosis of disorders in a subject.

Abstract: The present invention provides a method for detecting a mutation in a nucleic acid molecule which comprises contacting the nucleic acid molecule with a probe. The probe comprises two covalently linked nucleic acid segments under conditions such that the unlinked end of each segment of the probe is capable of hybridizing with the nucleic acid molecule. This mixture is then contacted with a ligase under conditions such that the two hybridized probe segments will ligate and bind the nucleic acid molecule if the nucleic acid molecule contains the mutation. One would then determine the presence of bound nucleic acid molecule(s) and thereby detect the mutation in the nucleic acid molecule.